A recent study has found that prolonged auras are common and are phenotypically similar to other auras. Based on the observed duration of aura symptoms, the researchers suggest reconsidering the use of the term “prolonged aura."
There is currently a limited amount of research involving prolonged aura (PA) in migraine—having 1 or more aura symptoms lasting between 60 minutes and 7 days. However, a recent study has found that prolonged auras are common and are phenotypically similar to other auras (non-PAs).
“Worldwide migraine is the third most common disorder and around 30% of sufferers experience migraine auras. Aura comprises completely reversible visual, sensory, or language symptoms (occurring respectively in 98%, 36% and 10% of auras),” wrote the authors of the study. They added, “We present a prospective study focusing on the frequency of occurrence and characteristics of PA.”
The researchers recruited 224 patients from the Headache Centers of Pavia and Trondheim who suffered from migraine with aura between October 2012 and July 2014. Patients were followed until May 2015 and were asked to record characteristics of 3 consecutives attacks in an ad hoc aura diary, where they would describe the visual, sensory, and dysphasic aura symptoms, as well as the duration.
To read more on migraine and visual quality of life, click here.
Of the patients, 72 recorded 3 consecutive auras, resulting in 216 recorded auras. Of these patients, 19 experienced at least 1 PA, with 9 patients experiencing 3 and 10 patients experiencing 1 or 2.
PAs and non-PAs with were compared based on 20 features. PAs were characterized by a higher frequency of non-visual symptoms. The authors observed the same results when comparing auras with a minimum of 1 symptom lasting more than 2 hours and those lasting more than 4 hours with others.
Overall, the authors noted that their findings show that, phenotypically, PAs are similar to non-PAs and are fairly common with 17% of all auras being PA and with 26% of patients experiencing at least 1.
“This can be expected when if we consider the pathophysiology of auras and recognize that aura symptoms with a longer duration are likely to be related to a cortical spreading depression proceeding across a longer path on the respective brain area,” they wrote.
The authors also note that their findings suggest the need to reconsider the use of the term “prolonged aura,” which is currently defined as more than 60 minutes and less than a week. Because aura symptoms lasted less 4 hours in 95% of the cases, having that symptoms for up to 4 hours should be considered typical, they argue. Based on this, prolonged aura would be considered aura symptoms lasting more than 4 hours.
Reference:
Viana M, Sances G, Nappi G, et al. Prolonged migraine aura: insights from a prospective diary-aided study [published online August 31, 2018]. doi: https://doi.org/10.1186/s10194-018-0910-y.
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen